NASDAQ · ICUI
ICU Medical, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ICUI: Nov 05, 2026
ICU Medical, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $1.75. The reported EPS for the same quarter last year was $1.66.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $1.75 | $1.81 | $1.69 | 4 |
| Dec 2026 | $1.84 | $1.88 | $1.82 | 4 |
| Mar 2027 | $1.72 | $1.73 | $1.71 | 2 |
| Jun 2027 | $1.95 | $1.95 | $1.95 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · The Motley Fool · MarketBeat- RTTNews · Oct 23, 1:16 AM EDTSeaStar Reports Higher Survival In QUELIMMUNE Pediatric Kidney Injury Analysis(RTTNews) – SeaStar Medical Holding Corp. (ICU) on Thursday said that critically ill pediatric patients with sepsis-associated acute kidney injury who received QUELIMMUNE (SCD-PED) therapy had significantly higher survival rates than a historical comparison group in the primary a
- Zacks · Oct 12, 7:55 AM EDTZacks Industry Outlook Highlights ICU Medical, Neogen and Trulieve CannabisICU Medical, Neogen and Trulieve Cannabis offer distinct growth catalysts as medical products demand benefits from innovation, resilient procedures and evolving market opportunities.
- Zacks · Oct 9, 8:31 AM EDT3 Medical Product Stocks Positioned to Ride on the Industry TailwindsHere, we highlight three medical product stocks, ICUI, NEOG and TRLV, which are well positioned to benefit from industry tailwinds and could be worth adding to investors' portfolios.
- The Motley Fool · Sep 17, 6:15 PM EDTICU Medical CFO Sells 6,381 Shares for $1.1 MillionThe sale involved shares equal to 10% of the CFO's direct equity stake held prior to the transaction.
- The Motley Fool · Sep 16, 8:50 PM EDTICU Medical CFO Brian Bonnell Sells 9,307 SharesThe transaction involved shares equal to 13% of the stake held before the filing.
- Zacks · Sep 7, 3:38 PM EDTBAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin PressureBaxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.
- The Motley Fool · Aug 13, 7:48 PM EDTICU Medical (ICUI) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 6, 11:03 PM EDTICU Medical Q2 Earnings Call HighlightsICU Medical (NASDAQ:ICUI) reported second-quarter revenue of $548 million, up 6% organically and 1% on a reported basis, as growth in its consumables and infusion systems businesses helped offset continued pressure in Vital Care and the effects of the IV Solutions joint venture d
- Zacks · Aug 6, 7:30 PM EDTICU Medical (ICUI) Reports Q2 Earnings: What Key Metrics Have to SayWhile the top- and bottom-line numbers for ICU Medical (ICUI) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- Zacks · Aug 6, 7:10 PM EDTICU Medical (ICUI) Tops Q2 Earnings and Revenue EstimatesICU Medical (ICUI) delivered earnings and revenue surprises of +24.08% and +2.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Aug 6, 5:25 PM EDTICU Medical Bottom Line Retreats In Q2(RTTNews) – ICU Medical (ICUI) revealed a profit for second quarter that Drops, from the same period last year
- Zacks · Aug 4, 7:00 PM EDTBio-Rad Laboratories (BIO) Beats Q2 Earnings EstimatesBio-Rad (BIO) delivered earnings and revenue surprises of +11.97% and -0.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for ICU Medical, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.